Omic
Omic is a Seattle-based AI-native drug discovery company building autonomous AI scientists, digital patient models, and a multi-omics platform to serve individual researchers via tiered SaaS and pharma/biotech enterprises via custom contracts and pipeline asset licensing.
- Company typePrivate
- Founded2017
- HeadquartersSeattle, United States
- Headcount1–10
- GTM typeB2B and B2C
- OfferingSoftware
What Omic does
Omic is a privately held AI-driven drug discovery company founded in June 2017 and based in Seattle (remote-friendly), operating at the intersection of multi-omics computational biology and frontier AI. The company builds an integrated platform that combines specialized science models optimized for biological and chemical reasoning, an autonomous AI Scientist agent that executes the full research workflow from hypothesis generation through manuscript writing, Digital Patient Models that simulate drug response across patient populations, trillion-molecule virtual screening, virtual clinical trials, and an Attest self-learning knowledge layer that compounds institutional learning with every experiment. Omic reports #1 ranking on the GPQA Diamond benchmark at 93.3% accuracy, surpassing the 69.7% human PhD baseline and the leading general-purpose frontier models.
The company serves a dual customer base. Through a product-led growth motion, it offers tiered SaaS access (Free, Student at $15/month, Researcher at $99/month, Lab at $129/seat/month) to individual scientists, students, and academic researchers. Through an enterprise field-sales motion, it provides custom contracts to pharma and biotech organizations, including proprietary drug discovery models, digital patient and digital trials pipelines, SSO/SAML, custom MCP integrations, and dedicated computational biology support. A third revenue stream is asset licensing of AI-discovered therapeutic programs — currently four programs in lead optimization across oncology, infectious disease, cardiovascular, and hematology indications (MYR-001, GLC-001, IMO-001, GPR-001, alongside earlier ONC-001, INF-001, HEM-001, CVD-001 programs).
Omic has raised seed (2018), Series A (2021), and Series B (2024) funding and claims to have reached profitability in February 2021. As of September 2024, headcount was approximately 15 employees. The company has established core technology integrations with Benchling, Veeva Systems, Schrödinger, and Snowflake, and has progressively expanded its platform capabilities and pipeline breadth since its founding, with its most recent public milestone being the November 2025 GPQA-Diamond #1 achievement. No revenue, ARR, or enterprise customer logos are disclosed in the available material.
Omic firmographics
Firmographics- Name
- Omic
- Legal name
- Omic
- Website
- https://omic.ai
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Omic is a Seattle-based AI-native drug discovery company building autonomous AI scientists, digital patient models, and a multi-omics platform to serve individual researchers via tiered SaaS and pharma/biotech enterprises via custom contracts and pipeline asset licensing.
- Ownership category
- akta.pro rank
Omic industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Computer Related Services (541519)
- SIC
- Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Omic is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Omic business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Subscription Plans: Tiered subscription model from free entry to enterprise. Self-serve tiers (Free, Student $15/mo, Researcher $99/mo, Lab $129/seat/mo) with annual discount (2 months free). Enterprise custom pricing with dedicated support and proprietary capabilities.
- Enterprise Partnerships: Custom enterprise contracts including AI scientist deployment, proprietary drug discovery models, digital patient pipelines, SSO/SAML integration, custom integrations, and dedicated computational biology support with weekly syncs.
- Asset Licensing: License AI-discovered therapeutic programs. Four programs available in oncology, infectious disease, cardiovascular, and hematology - computationally validated, in lead optimization.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Free - Full AI scientist with daily limits |
| Subscription | Monthly | Student - For coursework and thesis research |
| Subscription | Monthly | Researcher - For working scientists shipping results |
| Per seat | Monthly | Lab - For teams that share data and results |
| Subscription | Multi-year contract | Enterprise - For pharma and large research organizations |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Omic product offering
Product offeringCore offering
Omic provides an AI-driven drug discovery platform that combines biological superintelligence with computational biology. The core offering is the AI Scientist platform — an autonomous system that ideates with researchers, forms and tests hypotheses, builds research tools, runs iterative experiments, performs complex data analyses, and writes journal-ready manuscripts. The platform extends to Digital Patient Models for predicting drug response across patient populations, trillion-molecule screening, virtual clinical trials, and an Attest knowledge layer that compounds organizational learning with every experiment.
Product overview
Omic is an AI-driven drug discovery platform combining biological superintelligence with computational biology. The platform centers on the AI Scientist (an IDE for science that autonomously ideates, forms hypotheses, designs experiments, and writes manuscripts), Digital Patient Models (computational simulations of patient populations from multi-omics data), the Drug Discovery Pipeline (trillion-molecule screening and lead optimization), Digital Trials (virtual clinical trials for derisking), and the Attest Knowledge Layer (self-learning knowledge system). The platform offers tiered pricing from Free through Enterprise, and includes four proprietary pipeline programs in lead optimization: MYR-001 (cancer/infectious disease), GLC-001 (glaucoma), IMO-001 (solid tumors), and GPR-001 (inflammatory pain/sickle-cell). Enterprise customers access proprietary models, pipelines, MCP server integrations, and dedicated support.
Differentiator
Problem solved
Functional benefit
Products and services
- AI Scientist Platform
- Enterprise Drug Discovery Suite
- MYR-001
- GLC-001
- IMO-001
- GPR-001
Quantifiable outcome
- 93.3% accuracy on GPQA Diamond graduate-level science benchmark
- +3 more outcomes
Companies that use Omic
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Omic technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability11 records
Feature7 records
Omic partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- BenchlingcoreConnector integration for Omic enterprise platform. Benchling is a life sciences R&D platform used for lab notebook management, molecular biology, and discovery workflows. Omic integrates with Benchling to enable scientists to query proprietary compound libraries and screening results.
- Veeva SystemscoreConnector integration for Omic enterprise platform. Veeva provides cloud-based software for life sciences including clinical trials, regulatory affairs, and commercial operations. Omic integrates with Veeva for clinical and regulatory data access.
- SchrödingercoreConnector integration for Omic enterprise platform. Schrödinger is a scientific leader in computational chemistry and molecular modeling. Omic integrates with Schrödinger for chemistry-related computations and molecular dynamics.
- SnowflakecoreConnector integration for Omic enterprise platform. Snowflake provides cloud data warehousing and analytics. Omic integrates with Snowflake for data pipeline configuration and large-scale data analysis.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Omic competitors and assessment
Company assessmentEmerging players
- Owkin: AI biotech company applying machine learning to patient-derived data for drug discovery and clinical development. Comparable overlap in using AI to analyze clinical and multi-omics data and predict drug response, similar to Omic's Digital Patient models.
- Cradle Bio: AI platform for protein engineering and biologically relevant molecule design. Comparable in applying AI to biology and offering a self-serve SaaS platform, although focused on proteins rather than small molecules.
Direct peers
- Isomorphic Labs: Alphabet-owned AI drug discovery company applying deep learning to pharma R&D. Comparable in ambition to combine AI with drug discovery pipelines, with substantially more capital.
- Schrödinger: Physics-based computational chemistry platform for molecular simulation and drug discovery. Direct overlap with Omic's trillion-molecule screening and chemistry capabilities, and a listed Omic integration partner.
- Genesis Therapeutics: AI-driven drug discovery platform combining molecular AI with generative chemistry and internal pipeline programs. Direct competitor in AI small molecule discovery similar to Omic's pipeline assets.
- Atomwise: AI small molecule discovery platform using convolutional neural networks for hit identification. Direct competitor in the AI-driven small molecule screening space that Omic targets with its trillion-molecule screening feature.
- Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning for target identification and lead optimization. Closely comparable business model to Omic with both platform and internal pipeline assets.
- Xaira Therapeutics: AI-first drug discovery company founded with billion-dollar-plus funding. Comparable focus on applying frontier AI models to drug discovery and developing internal pipeline assets.
- Insitro: Machine learning-driven drug discovery platform partnering with pharma to develop therapeutics. Compares directly to Omic's enterprise AI drug discovery approach and pipeline strategy.
Broad incumbents
- BenevolentAI: Clinical-stage AI drug discovery company with both platform and pipeline assets. Comparable hybrid model of AI platform with internal therapeutic programs, though more mature and publicly listed.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Omic social profiles
Digital presenceOmic financial estimates
Financial estimateRevenue estimate
Valuation estimate
Omic leadership team
Management profileNumber of profiles
Omic funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Omic M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Omic
What does Omic do?
Omic provides an AI-driven drug discovery platform that combines biological superintelligence with computational biology. The core offering is the AI Scientist platform — an autonomous system that ideates with researchers, forms and tests hypotheses, builds research tools, runs iterative experiments, performs complex data analyses, and writes journal-ready manuscripts. The platform extends to Digital Patient Models for predicting drug response across patient populations, trillion-molecule screening, virtual clinical trials, and an Attest knowledge layer that compounds organizational learning with every experiment.
Is Omic a public or private company?
Omic is a private company. It is classified as venture growth investor backed and is currently operating.
When was Omic founded?
Omic was founded in 2017. It employs 1 to 10 people.
Where is Omic based?
Omic is headquartered in Seattle, United States, in the North America region.
How does Omic make money?
Three revenue lines are on record. Subscription Plans are the primary driver. The others are enterprise Partnerships and asset Licensing.
Who are Omic's main competitors?
Emerging players on record are Owkin and Cradle Bio. Direct peers are Isomorphic Labs, Schrödinger, Genesis Therapeutics, Atomwise, Recursion Pharmaceuticals, Xaira Therapeutics and Insitro. BenevolentAI is listed as a broad incumbent.
Does Omic have an API?
Yes. API access is available on the Student plan tier ($15/month). The API enables programmatic access to the AI scientist platform, allowing developers to integrate AI-driven drug discovery capabilities into their own workflows.
What industry is Omic in?
Omic's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 5132 and its SIC code is 7372.